Annovis Bio Files 2024 10-K

Ticker: ANVS · Form: 10-K · Filed: Mar 21, 2025 · CIK: 1477845

Annovis Bio, Inc. 10-K Filing Summary
FieldDetail
CompanyAnnovis Bio, Inc. (ANVS)
Form Type10-K
Filed DateMar 21, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

Related Tickers: ANVS

TL;DR

Annovis Bio (ANVS) dropped its 2024 10-K. Check financials & strategy.

AI Summary

Annovis Bio, Inc. filed its 2024 10-K on March 21, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly QR Pharma, Inc., is based in Malvern, PA, and operates in the pharmaceutical preparations sector. Key financial details and operational highlights for 2024 are presented in this annual report.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Annovis Bio's financial health, strategic direction, and risks for the fiscal year 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Annovis Bio faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 10519933 — Total Assets (Reported for the fiscal year 2024)
  • 14141521 — Total Liabilities (Reported for the fiscal year 2024)

Key Players & Entities

  • Annovis Bio, Inc. (company) — Filer of the 10-K
  • QR Pharma, Inc. (company) — Former name of Annovis Bio, Inc.
  • Malvern, PA (location) — Business and mailing address
  • 2024-12-31 (date) — Fiscal year end
  • 2025-03-21 (date) — Filing date of the 10-K

FAQ

What is Annovis Bio's primary business activity?

Annovis Bio, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code [2834].

When did Annovis Bio change its name from QR Pharma, Inc.?

The company's name change from QR Pharma, Inc. to Annovis Bio, Inc. occurred on December 2, 2009.

What is the fiscal year end for Annovis Bio?

Annovis Bio's fiscal year ends on December 31st.

What are the key inputs used in Annovis Bio's fair value measurements for warrants?

The filing indicates that Annovis Bio uses inputs such as Share Price, Risk-Free Interest Rate, Price Volatility, Expected Term, and Exercise Price for its fair value measurements of warrants, with these inputs being classified under Level 3 of the fair value hierarchy for both December 31, 2024, and December 31, 2023.

What is the SEC file number for Annovis Bio?

The SEC file number for Annovis Bio is 001-39202.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 21, 2025 regarding Annovis Bio, Inc. (ANVS).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.